News coverage about Intellia Therapeutics (NASDAQ:NTLA) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intellia Therapeutics earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.3346427005738 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Investor’s Alert (Volatility Analysis) – Intellia Therapeutics Inc., (NASDAQ: NTLA) – Stock Watch (stocksnewstimes.com)
- Investors Alert on Intellia Therapeutics Inc. (NTLA) – Wall Street Morning (wallstreetmorning.com)
- Sizzling Healthcare stock Alert- Intellia Therapeutics Inc. (NTLA) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Moving averages give many trading signals on Intellia Therapeutics Inc. (NTLA) – Wall Street Morning (wallstreetmorning.com)
- Intellia Therapeutics Inc. (NTLA) Lacking Vigorous Positions in Performance Measures – Stock News Stop (stockmarketstop.com)
A number of brokerages have weighed in on NTLA. Oppenheimer reiterated a “hold” rating on shares of Intellia Therapeutics in a research report on Monday, December 18th. TheStreet lowered Intellia Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, December 14th. BidaskClub lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. Zacks Investment Research raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Jefferies Group reissued a “buy” rating and issued a $36.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $30.17.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.06. The company had revenue of $7.30 million for the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The business’s revenue was up 49.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. equities research analysts anticipate that Intellia Therapeutics will post -1.68 earnings per share for the current fiscal year.
In other news, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Nessan Bermingham sold 111,500 shares of the company’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $20.34, for a total value of $2,267,910.00. Following the transaction, the chief executive officer now directly owns 696,000 shares in the company, valued at approximately $14,156,640. The disclosure for this sale can be found here. Insiders have sold 1,971,283 shares of company stock worth $37,137,161 in the last ninety days. 12.80% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/23/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-intellia-therapeutics-ntla-stock-price.html.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.